anbenitamab

1. 01:55
   ESMO 2026 现场信号

   In patients with HER2-positive advanced #breastcancer, the HER2-targeted bispecific antibody #anbenitamab plus albumin-bound docetaxel led to 24-month progression-free survival of

1. 17:21
   ESMO 2026 现场信号

   🔥Impressive results!
2. 17:08
   ESMO 2026 现场信号

   #ESMO26 | Anbenitamab + HB1801
3. 16:22
   ESMO 2026 现场信号

   Anbenitamab plus HB1801 . Her2 targeting Bispecific antibody from China and aluminum bound docetaxel vs THP . PFS HR 0.46 . Published in @nejm . Needle in Her2 positive is moving
4. 16:04
   ESMO 2026 现场信号

   HEALER: anbenitamab + HB1801 vs THP in HER2+ BC.
5. 15:58
   ESMO 2026 现场信号

   Binghe Xu presents data from the Healer trial in China evaluating anbenitamab (bispecific HER2ab) with lipo docetaxel vs THP for HER2+ MBC showing marked improvement in PFS and mod
6. 15:53
   ESMO 2026 现场信号

   Anbenitamab + HB1801 has better PFS than THP as first line therapy (control arm did poorly 14.3 mos)
7. 15:52
   ESMO 2026 现场信号

   Oral abstract #BreastCancer session at #ESMO26: very promising data with the bispecific anti-HER2 antibody #anbenitamab plus an experimental taxane #HB1801 as first-line therapy in
8. 15:52
   ESMO 2026 现场信号

   Anbenitamab+albumin-bound DTXのHEALER試験。
9. 14:35
   ESMO 2026 现场信号

   Presented at #ESMO26:
10. 14:30
    NEJM

    Anbenitamab 联合 HB1801 治疗 HER2 阳性晚期乳腺癌

    Anbenitamab 联合 HB1801 治疗 HER2 阳性晚期乳腺癌的研究由 NEJM 提前在线发表。所给正文仅标注“Ahead of Print”，未提供试验设计、样本量、疗效或安全性结果。

11. 06:41
    ESMO 2026 现场信号

    #ESMO26 | Anbenitamab – Phase III

1. 22:26
   ESMO 2026 现场信号

   Anbenitamab plus chemotherapy for previously treated HER2-positive GC/GEJC: Updated OS analysis of KC-WISE 🇨🇳

当前热度 69·可比范围峰值 100（10月24日 18:00）·近 24 小时可比范围变化 +884%·当前参与者 12

上图是参与者计数，下图是热度。趋势仅比较持续完整观测到的相同主体，范围可能小于当前热度统计。移动指针或点击图表查看每小时读数；键盘可用左右方向键切换。